Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Atrial Fibrillation Therapeutics Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 29 Aug 17

The "Atrial Fibrillation - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Atrial Fibrillation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Atrial Fibrillation - Overview
  3. Atrial Fibrillation - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Atrial Fibrillation - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Atrial Fibrillation - Companies Involved in Therapeutics Development
  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • Armetheon Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Cardiome Pharma Corp
  • Daiichi Sankyo Company Ltd
  • Dong-A Socio Holdings Co Ltd
  • Gilead Sciences Inc
  • InCarda Therapeutics Inc
  • Merck & Co Inc
  • N-Gene Research Laboratories Inc
  • Nissan Chemical Industries Ltd
  • OMEICOS Therapeutics GmbH
  • Verseon Corp

For more information about this report visit

View source version on

Business Wire

Last updated on: 29/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.